Brief: Tianjin TEDA Biomedical Engineering applies for trading resumption
April 24 (Reuters) - Tianjin TEDA Biomedical Engineering Co Ltd 8189.HK : * Acquisition of 51% equity interest in sjkgc * Deal for US$27 million * application has been made for resumption of trading with effect from 9:00 a.m. on 25 April 2016 * Source text for Eikon ID:nHKS6NrsNS ((For more news, please click here 8189.HK )) ((Bengaluru Newsroom; +91 80 6749 1130))
Recent news on Tianjin Teda Biomedical Engineering Co
See all newsBrief: Tianjin Teda Biomedical Engineering Appoints Lynn Li As Joint CEO, Re-Designates Sun Li As Joint CEO
Brief: Tianjin Teda Biomedical Engineering Signs AI Healthcare Cooperation Agreement
Brief: Tianjin Teda Biomedical Engineering Says Unit Enters Strategic Cooperation
Brief: Tianjin Teda Biomedical Engineering Says Zhongtai International Securities To Procure Placees
Brief: Tianjin Teda Biomedical Engineering Says Re-Designation Of He Xin To Non-Executive Director